Skip to main content
ConductScienceScienceDex
NIH funding notice PAR-20-029

Sustained Release of Antivirals for Treatment or Prevention of HIV (SRATP) (R01 Clinical Trial Not Allowed)

Closed on January 7, 2022.

Posted
October 10, 2019
Close date
January 7, 2022
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,556,673 in first-year total cost, median $778,337.

Most frequent study sections

  1. HIV Molecular Virology, Cell Biology, and Drug Development Study Section[HVCD]2

Most frequent institutions

  1. SCRIPPS FLORIDA1
  2. UNIVERSITY OF TEXAS RIO GRANDE VALLEY1
Competing awards under PAR-20-029 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2020An injectable hydrogel platform for sustained release of eCD4-Ig1R01AI154989-01APPEL, ERIC ANDREWFARZAN, MICHAEL R.SCRIPPS FLORIDA, FL$874,862HVCD
2020A targeted anti-HIV drug delivery to the GALT1R01AI147731-01A1ROY, UPALUNIVERSITY OF TEXAS RIO GRANDE VALLEY, TX$681,811HVCD

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

Start your CVHow the NIH biosketch works
PAR-20-029: Sustained Release of Antivirals for Treatment or Prevention of HIV (SRATP) (R01 Clinical Trial Not Allowed) | ScienceDex | ConductScience